Wendy Aspden-Curran
Corporate Officer/Principal bij APOGEE THERAPEUTICS, INC.
Oorsprong van het eerstegraads netwerk van Wendy Aspden-Curran
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 19 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Wendy Aspden-Curran via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| Washington University in St. Louis | College/University | Graduate Degree | |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Sales & Marketing | |
| OREXIGEN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Boxer Capital LLC
 Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Investment Managers | Corporate Officer/Principal | |
| SPYRE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
PellePharm, Inc.
 PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
| COGENT BIOSCIENCES, INC. | Biotechnology | Chairman | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Graduate Degree | |
| Stanford University | College/University | Doctorate Degree Doctorate Degree | |
| George Washington University | College/University | Undergraduate Degree | |
| Emory University | College/University | Undergraduate Degree | |
| McGill University | College/University | Undergraduate Degree | |
| San Diego State University | College/University | Undergraduate Degree | |
J.C. Flowers & Co. LLC
 J.C. Flowers & Co. LLC Investment ManagersFinance J.C. Flowers & Co. LLC (J.C. Flowers & Co.) is a private equity firm founded in 1998 by J. Christopher Flowers. The firm is headquartered in New York. | Investment Managers | Private Equity Analyst | |
Fordham University
 Fordham University Other Consumer ServicesConsumer Services Fordham University provides college and university. It offers undergraduate colleges and graduate & professional schools. The company was founded in 1841 and is headquartered in Bronx, NY. | College/University | Masters Business Admin | |
| Humboldt State University | College/University | Undergraduate Degree | |
| The Johns Hopkins University | College/University | Graduate Degree | |
| Pace University | College/University | Undergraduate Degree | |
| University of Arizona | College/University | Doctorate Degree | |
| The Rockefeller University | College/University | Graduate Degree | |
Tavistock Life Sciences Co.
 Tavistock Life Sciences Co. Investment ManagersFinance Tavistock Life Sciences Co (Tavistock Life Sciences Co.) is a venture capital firm founded in 2002. The firm is headquartered in San Diego, California. | Investment Managers | Private Equity Analyst | |
| NANOBIOTIX | Medical Specialties | Investor Relations Contact | |
| Weill Cornell Medical College | College/University | Doctorate Degree | |
Therasis, Inc.
 Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
AIG Global Investment Group, Inc.
 AIG Global Investment Group, Inc. Investment ManagersFinance Part of American International Group, Inc., AIG Global Investment Group, Inc. provides investment advisory services. The company is based in New York, NY. The CEO of the company is Win Jay Neuger. | Investment Managers | Corporate Officer/Principal | |
| The Wharton Health Care Alumni Association | Director/Board Member | ||
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
| University of the Philippines-Cebu | College/University | Doctorate Degree | |
Fairmount Funds Management LLC
 Fairmount Funds Management LLC Investment ManagersFinance Fairmount Funds Management LLC is an investment firm founded in 2016 and based in West Conshohocken, PA. The private company is dedicated to investing in promising new therapies pursued by biotechnology and life science companies. Fairmount Funds Management has subsidiaries in the United States. | Investment Managers | Corporate Officer/Principal | |
Fairmount Healthcare Feeder Fund Ltd.
 Fairmount Healthcare Feeder Fund Ltd. Investment Trusts/Mutual FundsMiscellaneous Fairmount Healthcare Feeder Fund Ltd. operates as an hedge fund which engages in pooling investment funds. The company is headquartered in Philadelphia, PA. | Investment Trusts/Mutual Funds | Director/Board Member | |
| VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| PROMETHEUS BIOSCIENCES, INC. | Biotechnology | Investor Relations Contact Chief Executive Officer | |
Novonate, Inc.
 Novonate, Inc. Medical SpecialtiesHealth Technology Novonate, Inc. engages in designing products that solve problems in neonatal care. The company is headquartered in Palo Alto, CA. | Medical Specialties | Founder | |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
| INVIVYD, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Viridian LLC
 Viridian LLC BiotechnologyHealth Technology Viridian LLC operates as a biopharmaceutical incubator. It focuses in the discovery and development of new molecular entities. The company was founded by Peter Harwin and Tomas Kiselak in 2016 and is headquartered in Philadelphia, PA. | Biotechnology | Founder Founder | |
Nalpropion Pharmaceuticals, Inc.
 Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ. | Managed Health Care | Director of Finance/CFO | |
| BIOMX INC. | Biotechnology | Investor Relations Contact | |
| DIANTHUS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Paragon Therapeutics, Inc. | Miscellaneous Commercial Services | Director/Board Member | |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistieken
Internationaal
| Verenigde Staten | 46 |
| Canada | 2 |
| Frankrijk | 2 |
| Filippijnen | 2 |
| Israël | 2 |
Sectoraal
| Health Technology | 21 |
| Consumer Services | 18 |
| Finance | 8 |
| Commercial Services | 3 |
| Miscellaneous | 2 |
Operationeel
| Director/Board Member | 44 |
| Corporate Officer/Principal | 37 |
| Independent Dir/Board Member | 21 |
| Undergraduate Degree | 18 |
| Director of Finance/CFO | 13 |
Sterkste connecties
| Insiders | |
|---|---|
| Jane Henderson | 25 |
| William Jones | 14 |
| Michael Henderson | 14 |
| Jennifer Fox | 13 |
| Peter Harwin | 11 |
| Mark Mckenna | 11 |
| Nimish Shah | 10 |
| Tomas Kiselak | 10 |
| Noël Kurdi | 9 |
| Rebecca Dabora | 8 |
| Carl Dambkowski | 8 |
| Monica Forbes | 5 |
| Andrew Gottesdiener | 5 |
| Dan Mulreany | 5 |
| Emily Cox | 3 |
- Beurs
- Insiders
- Wendy Aspden-Curran
- Bedrijfsconnecties
